Evogene Ltd. (TLV: EVGN)

Market Cap	32.03M
Revenue (ttm)	27.80M
Net Income (ttm)	-87.40M
Shares Out	6.79M
EPS (ttm)	-16.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	39,717
Open	452.00
Previous Close	452.00
Day's Range	450.10 - 487.00
52-Week Range	450.10 - 3,700.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 6, 2025

About Evogene

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Huma...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 142
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: EVGN

Financial Performance

In 2023, Evogene's revenue was $5.64 million, an increase of 236.72% compared to the previous year's $1.68 million. Losses were -$23.88 million, -10.36% less than in 2022.

Financial numbers in USD